Feasibility of Pulmonary Resection for Lung Cancer in Patients With Coronary Artery Disease or Atrial Fibrillation
Yoshitaka Kitamura(Juntendo University), Yoshinori Taniguchi(Kochi Medical School Hospital), Yohichiroh Ohtaki, Riken Kawachi, Hiroyuki Ishibashi(Tokyo Metropolitan Institute of Gerontology), Satoshi Teramukai(Kyoto University Hospital), Kenji Suzuki(Juntendo University), Yasushi Shimada, H Horio, Shigeto Nishikawa, Shinichi Toyooka(Okayama University Hospital), Yukiko Terada, Hajime Ichimura, Kentaro Okuda, Tomokazu Murakawa(The University of Osaka), Naoki Takahashi(University of Fukui), Taku Omori, Yuki Takahashi, Satoshi Shiono, Ryu Kanzaki(Osaka International Cancer Institute), Yuji Mizuno(Saiseikai Kumamoto Hospital), Takashi Eguchi, Jun Arikura, Teruo Iwata, Jiro Okami(Osaka Medical Center for Cancer and Cardiovascular Diseases), Wataru Nishio(Kobe University), M. Isaka, Hiroyuki Agatsuma, Hiroshi Date(Kyoto University), Osamu Kawashima, Yoshihisa Kadota, Yoshio Tsunezuka(Ishikawa Prefectural Central Hospital), Yoshihisa Nakagawa(Shiga University of Medical Science), Sou Ueda, Masayoshi Miyajima, Rintaro Nakajima, Hajime Nakamura(Kobe University), Makoto Sonobe(Kyoto University Hospital), Ayato Hayashi, Noriko Tanaka(National Center for Global Health and Medicine), Takuya Hashimoto(Kitasato University), Yohei Kobayashi(Osaka Red Cross Hospital), Nobuharu Hanaoka, T. Takemoto, Masaki Naito(Osaka Hospital), K Narita, Nobuo Tsunooka, Ryuichi Waseda, Hiroyasu Yokomise(Kagawa University), Hiroshi Haneda(Nagoya City University)
Cited by 11
Related Papers
Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial
|The Lancet|2022|1.6k
A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)
|Journal of Thoracic Oncology|2011|656
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|642
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582